#TSP TruSpine Technologies PLC – Result of 2025 AGM December 10, 2025 – Posted in: TruSpine Plc (TSP)

TSP Advanced Technologies plc, the medical device company focused on the spinal (vertebral) stabilisation market, announces that at its 2025 AGM held earlier today all resolutions were duly passed. Details of the votes received will be available shortly on the Company’s website. The Directors of the Company are responsible for the release of this announcement. -END- TSP Investor Hub https://truspinetech.com/aqse-rule-4-14 TSP Advanced Technologies plc Tel: +44 (0)20 7118 0852 Geoff Miller, Non-executive Chairman Cairn…

#TSP TruSpine Technologies PLC – Delay to the publication of accounts & Suspension October 1, 2025 – Posted in: TruSpine Plc (TSP)

TruSpine Technologies Plc, the medical device company focused on the spinal (vertebral) stabilisation market, announces a delay to the completion and publication of its audited accounts for the year to 29 March 2025. Accordingly, pursuant to Rule 5.1 of the AQSE Growth Market Access Rulebook, a temporary suspension of trading in the Company’s shares will take effect from 08:00 today (1 October 2025). The Company anticipates that it will be in a position to publish…

#VELA investee co. #KING Igraine PLC – Maiden Exercise of Investment Rights Over GEM Energia December 13, 2024 – Posted in: Vela Technologies Plc (VELA)

Igraine plc (AQSE: KING), an investing company focused on the development of battery energy storage and life sciences sectors, is pleased to update its shareholders regarding its exercise of investment rights with GEM Energia. As announced on 21 October 2024 and further to the announcement of 2 December 2024, Igraine secured the exclusive investment rights over GEM Energia Limited and its Special Purpose Vehicles, including a right of first refusal on all current and future…

#TSP TruSpine Technologies PLC – Investor Presentation September 30, 2024 – Posted in: TruSpine Plc (TSP)

TruSpine Technologies plc, (AQSE: TSP) the medical device company focused on the development of its pioneering “screwless,” spinal (vertebral) stabilisation systems, is pleased to announce that Geoffrey Miller and Samuel Ogunsalu, directors of the Company, will provide a live presentation relating to the Final Results via Investor Meet Company on 8 October 2024, 09:30 BST. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company…

#TSP TruSpine Technologies PLC – Final Results – Posted in: TruSpine Plc (TSP)

TruSpine Technologies plc, (AQSE: TSP) the medical device company focused on the development of its pioneering “screwless,” spinal (vertebral) stabilisation systems, reports its full year results for the year ended 29 March 2024. The Company continues to be in a pre-revenue development phase and remains loss making at this stage of its development. The loss before taxation for the year was £702k (2023: £853k) after administrative expenses of £656k (2023: £846k). The R&D tax…

#TSP TruSpine Technologies PLC – New Interactive Investor Hub June 7, 2024 – Posted in: TruSpine Plc (TSP), Uncategorized

TruSpine Technologies Plc, the medical device company focused on the spinal (vertebral) stabilisation market, is pleased to announce the launch of its new Interactive Investor Hub. For both existing and prospective shareholders, the new investor hub brings all TruSpine content into a single integrated platform to better inform and engage with investors and stakeholders, including: ● Regulatory announcements ● Reports ● Presentations ● Educational material ● Interviews ● Corporate research The investor hub also…

#TSP TruSpine Technologies PLC – Convertible Loan Note Conversion & Issue of Equity June 5, 2024 – Posted in: TruSpine Plc (TSP)

TruSpine Technologies Plc, the medical device company focused on the spinal (vertebral) stabilisation market, announces that, further to the announcement on 26 March 2024, the Company has elected to convert the Lender CLN Subscription of £200,000 into 13,333,333 new ordinary shares at a price of 1.5 pence per share (“CLN Shares”) pursuant to the terms of the CLN Instrument. Admission Application has been made for the CLN Shares to be admitted to trading…

#TSP Truspine Technologies PLC – Notice of 2023 AGM May 10, 2024 – Posted in: TruSpine Plc (TSP)

TruSpine Technologies Plc, the medical device company focused on the spinal (vertebral) stabilisation market, announces that notice of the Company’s 2023 annual general meeting (“2023 AGM”) will be sent to shareholders shortly. The 2023 AGM will be held at the offices of Hill Dickinson LLP at The Broadgate Tower, 20 Primrose Street, London, EC2A 2EW on 7 June 2024 at 11:30 am. A copy of the notice of the 2023 AGM, along with…

#TSP TruSpine Technologies PLC – IP Registration October 25, 2023 – Posted in: Blog, TruSpine Plc (TSP)

TruSpine Technologies plc, (AQSE: TSP) the medical device company focused on the development of its pioneering “screwless,” spinal (vertebral) stabilisation systems announces that it has, with the help of the Company’s newly appointed IP lawyers, published the original assignment of the Intellectual Property Rights to the Company as per the Original IP Agreement and Addendum. The patents acquired as part of the Intellectual Property Rights can be viewed at the following link: https://assignment.uspto.gov/patent/index.html#/patent/search/resultAssignee?assigneeName=TRUSPINE%20TECHNOLOGIES%20LIMITED Capitalised terms…

#TSP TruSpine PLC – Further re: FDA Update October 12, 2023 – Posted in: TruSpine Plc (TSP)

TruSpine Technologies plc, (AQSE: TSP) the medical device company focused on the development of its pioneering “screwless,” spinal (vertebral) stabilisation systems announces that, further to the announcement on 3 October 2023, the Company has submitted additional documentation and provided further clarification in regard to the questions raised by the U.S. Food and Drug Administration (“FDA”) relating to the Company’s FDA 510(k) application. TruSpine CEO Laurence Strauss commented: “We are pleased the US FDA have responded…